We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Vertex Pharmaceuticals Incorporated today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Lockheed Martin’s AI Factory uses a blend of open-source and proprietary AI models. It provides traceability, reliability, ...

Proficio Capital Partners cranked up its position in Vertex Pharmaceuticals by 46.6% during the fourth quarter, grabbing 978 ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.70% to $511.74 Monday, on what proved to be an all-around great trading ...